<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bonaca, Marc P.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">PEGASUS-TIMI 54 Subanalysis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-10-21 10:14:30</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">The PEGASUS-TIMI 54 trial demonstrated that continuing treatment with ticagrelor after 1 year following myocardial infarction protected patients from ischemic events and provided a more robust risk reduction compared to reinitiation in stable patients on aspirin monotherapy. Patients who were treated with only aspirin for &gt; 1year after myocardial infarction did not derive any benefit from reinitiation of P2Y12 inhibitor therapy and had an increased risk of bleeding.</style></abstract><number><style face="normal" font="default" size="100%">28</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>